617 related articles for article (PubMed ID: 34011224)
1. Robust classification-based molecular modelling of diverse chemical entities as potential SARS-CoV-2 3CL
Adhikari N; Banerjee S; Baidya SK; Ghosh B; Jha T
SAR QSAR Environ Res; 2021 Jun; 32(6):473-493. PubMed ID: 34011224
[TBL] [Abstract][Full Text] [Related]
2. Discovery of SARS-CoV-2 3CL
Wang Y; Xu B; Ma S; Wang H; Shang L; Zhu C; Ye S
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216507
[TBL] [Abstract][Full Text] [Related]
3. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
[TBL] [Abstract][Full Text] [Related]
4.
Bung N; Krishnan SR; Bulusu G; Roy A
Future Med Chem; 2021 Mar; 13(6):575-585. PubMed ID: 33590764
[No Abstract] [Full Text] [Related]
5. Drugs Repurposing Using QSAR, Docking and Molecular Dynamics for Possible Inhibitors of the SARS-CoV-2 M
Tejera E; Munteanu CR; López-Cortés A; Cabrera-Andrade A; Pérez-Castillo Y
Molecules; 2020 Nov; 25(21):. PubMed ID: 33172092
[TBL] [Abstract][Full Text] [Related]
6. Re
Karges J; Kalaj M; Gembicky M; Cohen SM
Angew Chem Int Ed Engl; 2021 May; 60(19):10716-10723. PubMed ID: 33606889
[TBL] [Abstract][Full Text] [Related]
7.
Liu H; Ye F; Sun Q; Liang H; Li C; Li S; Lu R; Huang B; Tan W; Lai L
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):497-503. PubMed ID: 33491508
[TBL] [Abstract][Full Text] [Related]
8. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL
Rawson JMO; Duchon A; Nikolaitchik OA; Pathak VK; Hu WS
Viruses; 2021 Jan; 13(2):. PubMed ID: 33498923
[TBL] [Abstract][Full Text] [Related]
9. Computational modeling of the bat HKU4 coronavirus 3CL
Abuhammad A; Al-Aqtash RA; Anson BJ; Mesecar AD; Taha MO
J Mol Recognit; 2017 Nov; 30(11):. PubMed ID: 28608547
[TBL] [Abstract][Full Text] [Related]
10. Active Learning and the Potential of Neural Networks Accelerate Molecular Screening for the Design of a New Molecule Effective against SARS-CoV-2.
Yassine R; Makrem M; Farhat F
Biomed Res Int; 2021; 2021():6696012. PubMed ID: 34124259
[TBL] [Abstract][Full Text] [Related]
11. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
Manelfi C; Gossen J; Gervasoni S; Talarico C; Albani S; Philipp BJ; Musiani F; Vistoli G; Rossetti G; Beccari AR; Pedretti A
Molecules; 2021 Feb; 26(4):. PubMed ID: 33557115
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B
J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL
Stille JK; Tjutrins J; Wang G; Venegas FA; Hennecker C; Rueda AM; Sharon I; Blaine N; Miron CE; Pinus S; Labarre A; Plescia J; Burai Patrascu M; Zhang X; Wahba AS; Vlaho D; Huot MJ; Schmeing TM; Mittermaier AK; Moitessier N
Eur J Med Chem; 2022 Feb; 229():114046. PubMed ID: 34995923
[TBL] [Abstract][Full Text] [Related]
14. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
[TBL] [Abstract][Full Text] [Related]
15. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL
Du R; Cooper L; Chen Z; Lee H; Rong L; Cui Q
Antiviral Res; 2021 Jun; 190():105075. PubMed ID: 33872675
[TBL] [Abstract][Full Text] [Related]
16. Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease.
Su H; Yao S; Zhao W; Zhang Y; Liu J; Shao Q; Wang Q; Li M; Xie H; Shang W; Ke C; Feng L; Jiang X; Shen J; Xiao G; Jiang H; Zhang L; Ye Y; Xu Y
Nat Commun; 2021 Jun; 12(1):3623. PubMed ID: 34131140
[TBL] [Abstract][Full Text] [Related]
17. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
[TBL] [Abstract][Full Text] [Related]
18. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
19. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL
Jade D; Ayyamperumal S; Tallapaneni V; Joghee Nanjan CM; Barge S; Mohan S; Nanjan MJ
Eur J Pharmacol; 2021 Jun; 901():174082. PubMed ID: 33823185
[TBL] [Abstract][Full Text] [Related]
20. Suggestion of active 3-chymotrypsin like protease (3CL
Mozafari Z; Chamjangali MA; Arashi M; Goudarzi N
SAR QSAR Environ Res; 2021 Nov; 32(11):863-888. PubMed ID: 34634208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]